Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteers.
Age range
18 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Phylum Level Mean Proportional Relative Abundance
Timeframe: Day 30
Phylum Level Mean Proportional Relative Abundance
Timeframe: Baseline
Phylum Level Mean Proportional Relative Abundance
Timeframe: Day 5
Phylum Level Mean Proportional Relative Abundance
Timeframe: Day 10
Bacterial DNA Per Gram of Stool
Timeframe: Baseline
Bacterial DNA Per Gram of Stool
Timeframe: During Therapy up to Day 6
Bacterial DNA Per Gram of Stool
Timeframe: End of Therapy up to Day 10
Order Level Mean Proportional Relative Abundance
Timeframe: Baseline
Order Level Mean Proportional Relative Abundance
Timeframe: Day 5
Order Level Mean Proportional Relative Abundance
Timeframe: Day 10
Order Level Mean Proportional Relative Abundance
Timeframe: Day 30